<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sinclair, Heather Q.</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Ismail-Beigi, Faramarz</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">ACCORD Microvascular Outcomes</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2010</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2010-08-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">18-18</style></pages><abstract><style  face="normal" font="default" size="100%">Clinicians should consider the increase in total and cardiovascular disease-related mortality, weight gain, and risk of severe hypoglycemia prior to implementing an intensive glycemic therapy strategy according to findings from a substudy of the Action to Control Cardiovascular Risk in Diabetes [ACCORD; NCT00000620] trial.</style></abstract><number><style face="normal" font="default" size="100%">6</style></number><volume><style face="normal" font="default" size="100%">10</style></volume></record></records></xml>